drugset / Trial / NCT07006246
Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa
Phase 4
Active not recruiting
1900 enrolled
Professor Francois Venter
Bill and Melinda Gates Foundation · collab
NaSingle-groupOpen-labelPrevention
Summary
This is a funded implementation study designed to evaluate the efficacy of recruiting and retaining high-risk individuals on pre-exposure prophylaxis (PrEP) within multiple private pharmacies (and online platforms in South Africa)
Timeline
- Start
- 2023-05-19
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | 300 mg | Oral |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |
| Subject | emtricitabine | Other / unclassified | 200 mg | Oral |